No abstract

The cfficacy of an immunomodulator, Baypamun N, was tested in Ll0-month-old horses which were exposed to stress by weaning, transport and commingling with yearlings from different breeders (crowding). Verum (n = 26) and placebo animals (n = 27) received three intramuscular injections of the investigational preparations (days 0, 2, 9) starting at the day of commingling in one stable. The incidence of acute respiratory disease was high during the first 4 weeks after commingling. Approximately 50 ' / u of all horses showed seroconversion due to field infection by EHVl and EHV4 during the observation period. The clinical scores in the Baypamun N group were significantly reduced by 40.3% (P < 0.05) compared to the placebo group. The proportion of horses with purulcnt nasal discharge during the observation pcriod (4 weeks) was also significantly reduced by 58.7% (P < 0.01) in the Baypamun N group. Fifty per cent of thc horses injected with Raypamun N showed no purulent nasal discharge and therefore no signs of complicated disease of the upper respiratory airways in contrast to only 14.8 Yo in the non-protected placebo group. The challenge conditions studied in this investigation were rather severe because of the permanent exposure of Baypamun N treated individuals to the non-separated and untreated horses (n = 51). This indicates that treatment with Baypamun N is a successful tool to avoid severe clinical consequences of stress in young-horses.

The efficacy of an immunomodulator, Baypamun N, was tested in 10-20-day-old veal calves from different farms, which were exposed to stress by transport and commingling (crowding). Verum and placebo animals (n = 50, each group) received three intramuscular injections of the investigational products (days 0,2,4) starting the day of arrival on the farm. Data from 49 calves in each group could be used for statistical evaluation. Thc incidence of acutc bovine respiratory disease was anticipated to be high during the first 2 weeks after arrival on farm based on experience from other years. The clinical scores in the Baypamun N group were significantly reduced by 52.7% (T' < 0.001) compared to the placebo group. The number of antibiotic treatments was significantly reduced by 53.8% (P < 0.001) in the Bayparnun N group. Of the calves treated with Baypamun N, 51.02 Yu remained untreated with antibiotics during the first 2 weeks after arrival on the farm compared with only 16.3 YO of the placebo treated control calves (P < 0.001).